Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Retention 1Prostatic Neoplasms 1Lung Neoplasms 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Tamsulosin × 1 year × Clear all
NCT04147806 2026-04-03

PROSINT

Albert Einstein College of Medicine

Phase 1 Active not recruiting
31 enrolled
Genitourinary

Prostatic Neoplasms

NCT03609580 2025-10-24

POUR

Hackensack Meridian Health

Phase 1/2 Recruiting
127 enrolled
Thoracic

Lung Neoplasms, Urinary Retention

Data powered by HemOnc (CC BY 4.0) Colophon âš¡